Aurobindo Pharma USA, Inc. has initiated a voluntary recall of two lots of Quinapril and Hydrochlorothiazide Tablets USP 20mg / 12.5mg – fixed combination tablets indicated to lower blood pressure and treat hypertension – due to presence of Nitrosamine Drug Substance Related Impurity (NDSRI), N-Nitroso-Quinapril above the proposed interim limit. These impurities may increase the risk of cancer if people are exposed to them above acceptable levels over long periods of time. The lot numbers impacted are QE2021005-A and QE2021010-A. The tablets are pink colored, scored, round shaped, biconvex, film-coated tablets, debossed with “D” on the scored side and “19”on other side, supplied in 90’s HDPE bottle.
